2008 PBL Cat_mech_r.qxd:PBL Catalog.mech 11/29/07 1:51 PM Page 41
Figure 2A: IFN-β dose-dependency on the Figure 2B: IFN-β dose-dependency on the
neutralizing effects of anti-IFN-β Abs neutralizing effects anti-IFN-β Abs
(Part I) (Part II)
o
n
z
a
t
i
t
i
o
n
ali
z
a
ali
N
e
utr
%
N
e
utr
%
Ab Dilution [IFN] (U/ml)
Figure 3A: Specificity of NAb assay: Figure 3B: Specificity of NAb assay:
Abs screened in AVA without IFN-β Abs screened in AVA with IFN-β
t
i
o
n
z
a
V
C
ali
%
N
e
utr
%
Ab Dilution Ab Dilution
Neutralization Neutralization Intra-Assay Precision (CV%) Inter-Assay Precision (CV%)
Ab Product # Titer (U/ml) Titer (U/ml) Ab at 50% CPE Ab Screen
21460-1 4.19 x 10
4
5.79 x 10
4
18.3 10.8
21470-1 4.94 x 10
4
9.89 x 10
4
11.7 9.67
21465-1 4.19 x 10
4
2.47 x 10
4
8.23 6.48
21400-1 2.12 x 10
4
5.79 x 10
4
9.18 8.26
31410-1 1.24 x 10
5
1.67 x 10
5
8.05 5.09
21450-1 4.09 x 10
4
1.61 x 10
4
23.6 14.9
Table 2:NAb activity and assay precision.
See page 34 for antibodies to Human Interferon Beta
www.interferonsource.com Tel: +1 732-777-9123
I
Fax: +1 732-777-9141
41
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62